Clinical Scorecard: Atherosclerosis Risk in Women with Polycystic Ovary Syndrome: Beyond Comorbid Conditions

At a Glance

Key Highlights

• Women with PCOS have a significantly higher 25-year cumulative incidence of acute coronary syndrome and ischemic stroke compared to controls (3.4% vs. 2.0%).
• PCOS is independently associated with increased risk of acute myocardial infarction (HR 1.86) and ischemic stroke (HR 1.83) after adjusting for multiple comorbidities and medications.
• The increased risk of recurrent cardiovascular events and composite outcomes in PCOS persists despite adjustment for medications including statins, metformin, and hormonal therapies.

Guideline-Based Recommendations

Diagnosis

• Recognize PCOS as a prevalent endocrinopathy in reproductive-age women with potential cardiovascular implications.
• Consider comprehensive cardiovascular risk assessment in women diagnosed with PCOS, including evaluation for hypertension, diabetes, and dyslipidaemia.

Management

• Address modifiable cardiovascular risk factors aggressively in women with PCOS.
• Monitor and manage comorbid conditions such as hypertension, type 2 diabetes, and dyslipidaemia to reduce atherosclerotic risk.
• Medication use (e.g., metformin, statins, hormonal therapies) does not appear to modify the increased cardiovascular risk associated with PCOS, highlighting the need for tailored risk reduction strategies.

Monitoring & Follow-up

• Implement long-term follow-up for cardiovascular events in women with PCOS, given higher rates of recurrent events.
• Regularly assess cardiovascular health and risk factor control in this population.

Risks

• PCOS independently increases the risk of atherosclerotic cardiovascular disease including acute myocardial infarction and ischemic stroke.
• Increased risk is not fully explained by traditional comorbidities or medication use.
• Potential underdiagnosis of milder PCOS cases and lack of adiposity data may affect risk stratification.

Patient & Prescribing Data

Women with PCOS identified from a large Danish nationwide registry (>25,000 individuals) compared to matched female controls.

Use of medications such as statins, metformin, hormonal therapies, and others did not significantly alter the association between PCOS and cardiovascular outcomes, indicating persistent elevated risk despite treatment.

Clinical Best Practices

• Incorporate cardiovascular risk assessment into routine care for women with PCOS, including evaluation of female-specific risk factors.
• Educate patients and families about the increased cardiovascular risk associated with PCOS during reproductive years.
• Collaborate across specialties (cardiology, endocrinology, gynecology) to optimize prevention and management of cardiovascular disease in women with PCOS.
• Recognize the importance of early identification and management of modifiable risk factors to reduce long-term atherosclerotic risk.

References

• Polycystic ovarian syndrome and long-term risk of acute myocardial infarction and ischaemic stroke, Havers-Borgersen et al.